Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been given an average rating of “Moderate Buy” by the fifteen research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $30.2727.

A number of brokerages have recently commented on BCAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Guggenheim initiated coverage on Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective on the stock. The Goldman Sachs Group upped their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Finally, Morgan Stanley upped their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th.

Insider Activity at Bicara Therapeutics

In other news, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total value of $807,800.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $28.42, for a total value of $284,200.00. Following the sale, the chief executive officer directly owned 362,152 shares in the company, valued at approximately $10,292,359.84. The trade was a 2.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 88,450 shares of company stock valued at $2,366,675 over the last ninety days. 13.80% of the stock is owned by company insiders.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new position in shares of Bicara Therapeutics during the 1st quarter worth approximately $248,000. Woodline Partners LP grew its holdings in Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after purchasing an additional 72,998 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Bicara Therapeutics by 36.8% during the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after purchasing an additional 180,833 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after purchasing an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter.

Bicara Therapeutics Trading Up 1.5%

NASDAQ:BCAX opened at $26.27 on Friday. Bicara Therapeutics has a twelve month low of $9.57 and a twelve month high of $30.99. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -9.45 and a beta of -0.81. The stock has a fifty day simple moving average of $25.08 and a 200-day simple moving average of $21.16.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, equities research analysts predict that Bicara Therapeutics will post -3.42 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.